Faculty

Michael Frederick Press

Michael Frederick Press

Professor of Pathology;Harold E. Lee Chair in Breast Cancer Research;Director of Breast Cancer Analysis Lab
Pathology
NTT 1441 Eastlake Ave Health Sciences Campus Los Angeles

Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach Hum Mol Genet. 2022 Sep 10; 31(18):3133-3143. . View in PubMed

Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer Cancers (Basel). 2022 Jun 04; 14(11). . View in PubMed

Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer Ann Surg Oncol. 2022 May; 29(5):2882-2894. . View in PubMed

Correction to: Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer Ann Surg Oncol. 2022 May; 29(5):3064. . View in PubMed

A Systematic Review and Meta-Analysis of Smoking and Circulating Sex Hormone Levels Among Premenopausal Women Nicotine Tob Res. 2022 Mar 15. . View in PubMed

A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone Appl Immunohistochem Mol Morphol. 2022 04 01; 30(4):237-245. . View in PubMed

A careful reassessment of anthracycline use in curable breast cancer NPJ Breast Cancer. 2021 Oct 08; 7(1):134. . View in PubMed

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response Nat Cancer. 2021 04; 2(4):400-413. . View in PubMed

Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry J Natl Cancer Inst. 2021 09 04; 113(9):1168-1176. . View in PubMed

Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women Nat Commun. 2021 07 07; 12(1):4198. . View in PubMed

Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy PLoS One. 2021; 16(5):e0251163. . View in PubMed

Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry Am J Hum Genet. 2021 04 01; 108(4):564-582. . View in PubMed

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE J Clin Oncol. 2021 01 01; 39(1):79-89. . View in PubMed

Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients Breast Cancer Res Treat. 2020 Nov; 184(2):311-324. . View in PubMed

Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer Cancer Med. 2020 09; 9(18):6463-6472. . View in PubMed

Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG) Clin Breast Cancer. 2020 06; 20(3):183-193. . View in PubMed

A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer Clin Breast Cancer. 2020 06; 20(3):e251-e260. . View in PubMed

Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers Cancer Discov. 2020 01; 10(1):86-103. . View in PubMed

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07) Nat Commun. 2020 11 17; 11(1):5824. . View in PubMed

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry Blood Adv. 2020 01 14; 4(1):181-190. . View in PubMed

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer Clin Cancer Res. 2020 02 01; 26(3):566-580. . View in PubMed

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy Nat Commun. 2019 May 30; 10(1):2433. . View in PubMed

Role for polo-like kinase 4 in mediation of cytokinesis Proc Natl Acad Sci U S A. 2019 06 04; 116(23):11309-11318. . View in PubMed

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy Nat Commun. 2019 02 08; 10(1):657. . View in PubMed

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines JAMA Oncol. 2019 03 01; 5(3):366-375. . View in PubMed

Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform Breast Cancer Res Treat. 2018 Nov; 172(2):327-338. . View in PubMed

RNA-Seq of Circulating Tumor Cells in Stage II-III Breast Cancer Ann Surg Oncol. 2018 Aug; 25(8):2261-2270. . View in PubMed

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Arch Pathol Lab Med. 2018 11; 142(11):1364-1382. . View in PubMed

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer Lung Cancer. 2018 09; 123:91-98. . View in PubMed

Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines Cell Rep. 2018 11 27; 25(9):2617-2633. . View in PubMed

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update J Clin Oncol. 2018 07 10; 36(20):2105-2122. . View in PubMed

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE J Clin Oncol. 2018 03 10; 36(8):741-748. . View in PubMed

Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis Breast Cancer Res. 2018 01 22; 20(1):5. . View in PubMed

Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium PLoS Genet. 2017 Apr; 13(4):e1006719. . View in PubMed

Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry Cancer Epidemiol Biomarkers Prev. 2017 07; 26(7):1016-1026. . View in PubMed

HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib Mol Cancer Ther. 2017 01; 16(1):228-238. . View in PubMed

A functionally significant SNP in TP53 and breast cancer risk in African-American women NPJ Breast Cancer. 2017; 3:5. . View in PubMed

Human-derived normal mesenchymal stem/stromal cells in anticancer therapies J Cancer. 2017; 8(1):85-96. . View in PubMed

Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis Breast Cancer Res. 2017 01 13; 19(1):6. . View in PubMed

Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib JAMA Oncol. 2016 Oct 01; 2(10):1287-1294. . View in PubMed

Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer J Clin Oncol. 2016 Mar 20; 34(9):936-44. . View in PubMed

Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells Oncotarget. 2016 Feb 23; 7(8):9561-75. . View in PubMed

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial J Clin Oncol. 2016 Feb 10; 34(5):443-51. . View in PubMed

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1609-1618. . View in PubMed

Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation Practice Arch Pathol Lab Med. 2016 11; 140(11):1250-1258. . View in PubMed

Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry Hum Genet. 2016 10; 135(10):1145-59. . View in PubMed

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial Ann Oncol. 2016 06; 27(6):1041-1047. . View in PubMed

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials J Clin Oncol. 2016 10 10; 34(29):3518-3528. . View in PubMed

Genome-wide association studies in women of African ancestry identified 3q2621 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Hum Mol Genet. 2016 11 01; 25(21):4835-4846. . View in PubMed

Many private mutations originate from the first few divisions of a human colorectal adenoma J Pathol. 2015 Nov; 237(3):355-62. . View in PubMed

Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers J Mol Diagn. 2015 Sep; 17(5):487-95. . View in PubMed

Reduced risk of breast cancer associated with recreational physical activity varies by HER2 status Cancer Med. 2015 Jul; 4(7):1122-35. . View in PubMed

Non-coding RNAs derived from an alternatively spliced REST transcript (REST-003) regulate breast cancer invasiveness Sci Rep. 2015 Jun 08; 5:11207. . View in PubMed

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance Clin Cancer Res. 2015 May 01; 21(9):2065-74. . View in PubMed

Reply to EA. Rakha et al. J Clin Oncol. 2015 Apr 10; 33(11):1302-4. . View in PubMed

A Big Bang model of human colorectal tumor growth Nat Genet. 2015 Mar; 47(3):209-16. . View in PubMed

Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia Clin Epigenetics. 2015; 7:117. . View in PubMed

Molecular markers for breast cancer diagnosis, prognosis and targeted therapy J Surg Oncol. 2015 Jan; 111(1):81-90. . View in PubMed

Methodological Considerations in Estimation of Phenotype Heritability Using Genome-Wide SNP Data, Illustrated by an Analysis of the Heritability of Height in a Large Sample of African Ancestry Adults PLoS One. 2015; 10(6):e0131106. . View in PubMed

A comprehensive examination of breast cancer risk loci in African American women Hum Mol Genet. 2014 Oct 15; 23(20):5518-26. . View in PubMed

Genome-wide scan of 29,141 African Americans finds no evidence of directional selection since admixture Am J Hum Genet. 2014 Oct 02; 95(4):437-44. . View in PubMed

Meta-analysis of loci associated with age at natural menopause in African-American women Hum Mol Genet. 2014 Jun 15; 23(12):3327-42. . View in PubMed

HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics Breast Cancer Res Treat. 2014 May; 145(1):193-203. . View in PubMed

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update Arch Pathol Lab Med. 2014 Feb; 138(2):241-56. . View in PubMed

Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer Clin Cancer Res. 2014 Feb 01; 20(3):736-43. . View in PubMed

Characterization of HER2 status by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) Methods Mol Biol. 2014; 1180:181-207. . View in PubMed

A conceptual and methodological framework for investigating etiologic heterogeneity Stat Med. 2013 Dec 20; 32(29):5039-52. . View in PubMed

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol. 2013 Nov 01; 31(31):3997-4013. . View in PubMed

Genome-wide association study of age at menarche in African-American women Hum Mol Genet. 2013 Aug 15; 22(16):3329-46. . View in PubMed

Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial Ann Oncol. 2013 Jul; 24(7):1754-1761. . View in PubMed

A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry Nat Genet. 2013 Jun; 45(6):690-6. . View in PubMed

Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status BMC Cancer. 2013 May 04; 13:225. . View in PubMed

Genome-wide association studies identify four ER negative-specific breast cancer risk loci Nat Genet. 2013 Apr; 45(4):392-8398e1-2. . View in PubMed

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005) Breast Cancer Res Treat. 2013 Feb; 138(1):99-108. . View in PubMed

A genome-wide scan for breast cancer risk haplotypes among African American women PLoS One. 2013; 8(2):e57298. . View in PubMed

Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women Breast Cancer Res. 2013; 15(5):R90. . View in PubMed

A genome-wide association study of breast cancer in women of African ancestry Hum Genet. 2013 Jan; 132(1):39-48. . View in PubMed

A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11 Hum Mol Genet. 2012 Dec 15; 21(24):5373-84. . View in PubMed

Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis BMC Cancer. 2012 Dec 13; 12:597. . View in PubMed

Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades Cancer Epidemiol Biomarkers Prev. 2012 Oct; 21(10):1848-55. . View in PubMed

Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial Contraception. 2012 Sep; 86(3):238-43. . View in PubMed

Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries Breast Cancer Res. 2012 Jun 12; 14(3):R91. . View in PubMed

Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance J Clin Oncol. 2012 Feb 01; 30(4):357-61. . View in PubMed

Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans Hum Mol Genet. 2011 Nov 15; 20(22):4491-503. . View in PubMed

Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger Breast Cancer Res Treat. 2011 Nov; 130(2):587-97. . View in PubMed

Pathological characteristics of BRCA-associated breast cancers in Hispanics Breast Cancer Res Treat. 2011 Nov; 130(1):281-9. . View in PubMed

A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer Nat Genet. 2011 Oct 30; 43(12):1210-4. . View in PubMed

Identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry PLoS Genet. 2011 Oct; 7(10):e1002298. . View in PubMed

Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer J Clin Oncol. 2011 Sep 01; 29(25):3358-65. . View in PubMed

The landscape of recombination in African Americans Nature. 2011 Jul 20; 476(7359):170-5. . View in PubMed

Enhanced statistical tests for GWAS in admixed populations: assessment using African Americans from CARe and a Breast Cancer Consortium PLoS Genet. 2011 Apr; 7(4):e1001371. . View in PubMed

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy J Clin Oncol. 2011 Mar 01; 29(7):859-67. . View in PubMed

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens J Clin Oncol. 2011 Jan 10; 29(2):149-56. . View in PubMed

Genome-scale screen for DNA methylation-based detection markers for ovarian cancer PLoS One. 2011; 6(12):e28141. . View in PubMed

Fine scale mapping of the breast cancer 16q12 locus Hum Mol Genet. 2010 Jun 15; 19(12):2507-15. . View in PubMed

A case-control study of body mass index and breast cancer risk in white and African-American women Cancer Epidemiol Biomarkers Prev. 2010 Jun; 19(6):1532-44. . View in PubMed

Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer Clin Cancer Res. 2010 Feb 15; 16(4):1281-8. . View in PubMed

Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study Cancer Res. 2010 Jan 15; 70(2):575-87. . View in PubMed

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer J Clin Oncol. 2009 Nov 20; 27(33):5538-46. . View in PubMed

Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study J Clin Oncol. 2009 Nov 20; 27(33):5552-8. . View in PubMed

An admixture scan in 1,484 African American women with breast cancer Cancer Epidemiol Biomarkers Prev. 2009 Nov; 18(11):3110-7. . View in PubMed

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer J Clin Oncol. 2009 Aug 20; 27(24):3908-15. . View in PubMed

Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev. 2009 Aug; 18(8):2214-20.. View in PubMed

Relationship between migraine history and breast cancer risk among premenopausal and postmenopausal women Cancer Epidemiol Biomarkers Prev. 2009 Jul; 18(7):2030-4. . View in PubMed

Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers J Natl Cancer Inst. 2009 May 06; 101(9):615-8. . View in PubMed

Admixture mapping of 15,280 African Americans identifies obesity susceptibility loci on chromosomes 5 and X PLoS Genet. 2009 May; 5(5):e1000490. . View in PubMed

FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation Hum Mol Genet. 2009 May 01; 18(9):1692-703. . View in PubMed

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations J Clin Oncol. 2009 Mar 10; 27(8):1323-33. . View in PubMed

A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach Clin Breast Cancer. 2009 Feb; 9(1):16-22. . View in PubMed

Cancer Epidemiol Biomarkers Prev. 2009 Feb; 18(2):479-85. . View in PubMed

Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort BMC Cancer. 2009 Jan 30; 9:43. . View in PubMed

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer Br J Cancer. 2009 Jan 13; 100(1):89-95. . View in PubMed

HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer Clin Cancer Res. 2008 Dec 01; 14(23):7861-70. . View in PubMed

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer J Clin Oncol. 2008 Dec 01; 26(34):5544-52. . View in PubMed

Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: a case-control study Cancer Epidemiol Biomarkers Prev. 2008 Jul; 17(7):1723-30. . View in PubMed

Mitochondrial DNA G10398A variant is not associated with breast cancer in African-American women Cancer Genet Cytogenet. 2008 Feb; 181(1):16-9. . View in PubMed

Timing of menarche and first full-term birth in relation to breast cancer risk Am J Epidemiol. 2008 Jan 15; 167(2):230-9. . View in PubMed

The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer Breast Cancer Res. 2008; 10(4):R58. . View in PubMed

A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African Americans Cancer Res. 2007 Apr 15; 67(8):3565-8. . View in PubMed

Serum organochlorines and breast cancer: a case-control study among African-American women Cancer Causes Control. 2007 Feb; 18(1):29-39. . View in PubMed

EGFR, HER2 and VEGF pathways: validated targets for cancer treatment Drugs. 2007; 67(14):2045-75. . View in PubMed

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol. 2007 Jan 01; 25(1):118-45. . View in PubMed

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med. 2007; 131(1):18-43. . View in PubMed

How is Her-2/neu status established when Her-2/neu and chromosome 17 centromere are both amplified? Am J Clin Pathol. 2006 Nov; 126(5):673-4.. View in PubMed

Oral contraceptive use and risk of breast carcinoma in situ (United States) Cancer Causes Control. 2006 Nov; 17(9):1155-62. . View in PubMed

Receptor tyrosine kinase EphB4 is a survival factor in breast cancer Am J Pathol. 2006 Jul; 169(1):279-93. . View in PubMed

HER2 testing in breast cancer: NCCN Task Force report and recommendations J Natl Compr Canc Netw. 2006 Jul; 4 Suppl 3:S1-22; quiz S23-4. . View in PubMed

Breast cancer risk estimates for relatives of white and African American women with breast cancer in the Women's Contraceptive and Reproductive Experiences Study J Clin Oncol. 2006 Jun 01; 24(16):2498-504. . View in PubMed

Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer Cancer Epidemiol Biomarkers Prev. 2006 May; 15(5):946-54. . View in PubMed

Lifetime recreational exercise activity and breast cancer risk among black women and white women J Natl Cancer Inst. 2005 Nov 16; 97(22):1671-9. . View in PubMed

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials Clin Cancer Res. 2005 Sep 15; 11(18):6598-607. . View in PubMed

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab Breast Cancer Res Treat. 2005 Sep; 93(1):3-11. . View in PubMed

Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas Int J Gynecol Cancer. 2005 Sep-Oct; 15(5):952-63. . View in PubMed

Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology Br J Cancer. 2005 Aug 08; 93(3):364-71. . View in PubMed

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab Clin Breast Cancer. 2005 Aug; 6(3):240-6. . View in PubMed

Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging Cancer Res. 2005 Jul 01; 65(13):5907-16. . View in PubMed

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer J Clin Oncol. 2005 Apr 10; 23(11):2534-43. . View in PubMed

Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics' Breast Cancer Res Treat. 2005 Mar; 90(1):1-3. . View in PubMed

Racial differences in the familial aggregation of breast cancer and other female cancers Breast Cancer Res Treat. 2005 Feb; 89(3):227-35. . View in PubMed

Impact of reproductive factors and lactation on breast carcinoma in situ risk Int J Cancer. 2004 May 20; 110(1):102-9. . View in PubMed

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer J Natl Cancer Inst. 2004 May 19; 96(10):759-69. . View in PubMed

Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting Protein Eng Des Sel. 2004 Apr; 17(4):315-23. . View in PubMed

Identification of TP53 mutations in human cancers using oligonucleotide microarrays Methods Mol Med. 2004; 97:323-35. . View in PubMed

Lifetime recreational exercise activity and risk of breast carcinoma in situ Cancer. 2003 Nov 15; 98(10):2161-9. . View in PubMed

Antibody-mediated targeting of replication-competent retroviral vectors Hum Gene Ther. 2003 May 20; 14(8):789-802. . View in PubMed

P7 antigen expression in human breast cancer Clin Cancer Res. 2003 Jan; 9(1):201-6. . View in PubMed

Comparison of different antibodies for detection of progesterone receptor in breast cancer Steroids. 2002 Aug; 67(9):799-813. . View in PubMed

Heritable breast cancer in twins Br J Cancer. 2002 Jul 29; 87(3):294-300. . View in PubMed

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J Clin Oncol. 2002 Jul 15; 20(14):3095-105. . View in PubMed

The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results Ann Epidemiol. 2002 May; 12(4):213-21. . View in PubMed

Germ-line HER-2 variant and breast cancer risk by stage of disease Cancer Res. 2001 Dec 01; 61(23):8393-4. . View in PubMed

Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer Clin Cancer Res. 2001 Oct; 7(10):2984-97. . View in PubMed

Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer Cancer Res. 2001 Apr 01; 61(7):3212-9. . View in PubMed

Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor Cancer Res. 2000 Nov 01; 60(21):5946-9. . View in PubMed

Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis Cancer Res. 2000 May 15; 60(10):2716-22. . View in PubMed

p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma Gynecol Oncol. 2000 May; 77(2):237-42. . View in PubMed

Reduction of BRCA1 expression in sporadic ovarian cancer Gynecol Oncol. 2000 Mar; 76(3):294-300. . View in PubMed

p53 mutations and expression in breast carcinoma in situ Am J Pathol. 2000 Jan; 156(1):183-91. . View in PubMed

Assessment of novel anti-p185HER-2 monoclonal antibodies for internalization-dependent therapies Hybridoma. 1999 Dec; 18(6):487-95. . View in PubMed

The risk of angiosarcoma following primary breast cancer Br J Cancer. 1999 Oct; 81(3):532-6. . View in PubMed

The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer Semin Oncol. 1999 Aug; 26(4 Suppl 12):108-16. . View in PubMed

MDR1 gene expression in primary and advanced breast cancer Lab Invest. 1999 Mar; 79(3):271-80. . View in PubMed

Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas Nat Genet. 1999 Feb; 21(2):236-40. . View in PubMed

p53 mutations and expression in ovarian cancers: correlation with overall survival Int J Gynecol Pathol. 1999 Jan; 18(1):29-41. . View in PubMed

Prognostic significance of DNA content and S-phase fraction in epithelial ovarian carcinomas analyzed by image cytometry Gynecol Oncol. 1998 Oct; 71(1):3-13. . View in PubMed

Does estrogen receptor expression in normal breast tissue predict breast cancer risk? J Natl Cancer Inst. 1998 Jan 07; 90(1):5-7.. View in PubMed

Genomic semi-automated cycle sequencing as a sensitive screening technique for p53 mutations in frozen tumor samples Oncol Rep. 1998 Jan-Feb; 5(1):65-8. . View in PubMed

Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy Int J Radiat Oncol Biol Phys. 1997 Dec 01; 39(5):1059-68. . View in PubMed

Multispecimen tissue blocks in pathology: an improved technique of preparation Lab Invest. 1997 Nov; 77(5):541-2. . View in PubMed

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas J Clin Oncol. 1997 Aug; 15(8):2894-904. . View in PubMed

Telomerase activity in normal and neoplastic breast Clin Cancer Res. 1997 Apr; 3(4):627-31. . View in PubMed

WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium Am J Pathol. 1997 Jan; 150(1):167-75. . View in PubMed

Chicken ovalbumin upstream promoter--transcription factor (COUP-TF) expression in human endometrial cancer cell lines Anticancer Res. 1996 Nov-Dec; 16(6B):3371-6. . View in PubMed

Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization Oncogene. 1996 Jul 04; 13(1):63-72. . View in PubMed

Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma Hum Pathol. 1996 Jun; 27(6):561-6. . View in PubMed

Clonal analysis of bilateral breast cancer Clin Cancer Res. 1996 Apr; 2(4):743-8. . View in PubMed

Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome J Cancer Res Clin Oncol. 1996; 122(8):489-94. . View in PubMed

Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival Cancer Res. 1995 Dec 01; 55(23):5693-8. . View in PubMed

Expression patterns of immediate early transcription factors in human non-small cell lung cancerThe Lung Cancer Study Group. Oncogene. 1995 Oct 05; 11(7):1261-9. . View in PubMed

[Prognostic differentiation of ovarian carcinomas by immunohistochemical analysis of estrogen receptor expression] Geburtshilfe Frauenheilkd. 1995 Apr; 55(4):189-94. . View in PubMed

[Overexpression of p53 protein in ovarian carcinomas: correlation with histopathologic data and clinical course] Gynakol Geburtshilfliche Rundsch. 1995; 35 Suppl 1:93-7. . View in PubMed

Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis Cancer Res. 1994 Nov 01; 54(21):5675-82. . View in PubMed

Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study Fertil Steril. 1994 Sep; 62(3):485-90. . View in PubMed

Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression Cancer Res. 1994 May 15; 54(10):2771-7. . View in PubMed

Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor Cancer Res. 1993 Nov 01; 53(21):5188-92. . View in PubMed

Prognostic significance of estrogen receptor expression in ovarian cancerImmunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL). Anticancer Res. 1993 Nov-Dec; 13(6B):2489-96. . View in PubMed

Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease Cancer Res. 1993 Oct 15; 53(20):4960-70. . View in PubMed

Evaluating the effect of age on endometrial responsiveness to hormone replacement therapy: a histologic ultrasonographic, and tissue receptor analysis J Assist Reprod Genet. 1993 Jan; 10(1):47-52. . View in PubMed

Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk Epidemiol Rev. 1993; 15(1):17-35. . View in PubMed

Oncogene amplification and expressionImportance of methodologic considerations. Am J Clin Pathol. 1990 Aug; 94(2):240-1. . View in PubMed

Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues Oncogene. 1990 Jul; 5(7):953-62. . View in PubMed

HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer Arch Pathol Lab Med. 1990 Feb; 114(2):164-9. . View in PubMed

HER-2/neu oncogene amplification and expression in breast and ovarian cancers Prog Clin Biol Res. 1990; 354A:209-21. . View in PubMed

Subcellular distribution of estrogen receptor and progesterone receptor with and without specific ligand Am J Pathol. 1989 Nov; 135(5):857-64. . View in PubMed

Estrogen and progesterone receptors in meningiomas: comparison of nuclear binding, dextran-coated charcoal, and immunoperoxidase staining assays Neurosurgery. 1989 Oct; 25(4):546-52; discussion 552-3. . View in PubMed

Comparison of the quantity of estrogen receptors in human endometrium and myometrium by steroid-binding assay and enzyme immunoassay based on monoclonal antibodies to human estrophilin Am J Obstet Gynecol. 1989 Mar; 160(3):592-7. . View in PubMed

The effect of the alpha-emitting radionuclide lead-212 on human ovarian carcinoma: a potential new form of therapy Gynecol Oncol. 1989 Feb; 32(2):236-9. . View in PubMed

The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis Am J Clin Pathol. 1988 Sep; 90(3):233-9. . View in PubMed

Progesterone receptor distribution in the human endometriumAnalysis using monoclonal antibodies to the human progesterone receptor. Am J Pathol. 1988 Apr; 131(1):112-24. . View in PubMed

Subnuclear localization of the trans-activating protein of human T-cell leukemia virus type I J Virol. 1988 Mar; 62(3):680-6. . View in PubMed

Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor Endocrinology. 1988 Mar; 122(3):1165-75. . View in PubMed

Estrogen receptor localization in formalin-fixed, paraffin-embedded endometrium and endometriotic tissues Int J Gynecol Pathol. 1987; 6(2):140-51. . View in PubMed

Studies of the human c-myb gene and its product in human acute leukemias Science. 1986 Jul 18; 233(4761):347-51. . View in PubMed

Estrogen receptor localization in the female genital tract Am J Pathol. 1986 May; 123(2):280-92. . View in PubMed

Distribution of peroxidase and granulocytes in the human uterus Lab Invest. 1986 Feb; 54(2):188-203. . View in PubMed

Structure and dynamics of the estrogen receptor J Steroid Biochem. 1986 Jan; 24(1):1-7. . View in PubMed

Immunocytochemical identification of estrogen receptor in ovarian carcinomasLocalization with monoclonal estrophilin antibodies compared with biochemical assays. Lab Invest. 1985 Sep; 53(3):349-61. . View in PubMed

Immunoelectron microscopic localization of estrogen receptor with monoclonal estrophilin antibodies J Histochem Cytochem. 1985 Sep; 33(9):915-24. . View in PubMed

Studies of the putative transforming protein of the type I human T-cell leukemia virus Science. 1985 Jun 21; 228(4706):1427-30. . View in PubMed

Endometrial "sarcomas" complicating ovarian thecoma, polycystic ovarian disease and estrogen therapy Gynecol Oncol. 1985 Jun; 21(2):135-54. . View in PubMed

Immunohistochemical assessment of estrogen receptor distribution in the human endometrium throughout the menstrual cycle Lab Invest. 1984 Nov; 51(5):495-503. . View in PubMed

An immunocytochemical method for demonstrating estrogen receptor in human uterus using monoclonal antibodies to human estrophilin Lab Invest. 1984 Apr; 50(4):480-6. . View in PubMed

Epithelial peroxidase and endometrial granulocytes in the normal cyclic human endometrium J Clin Endocrinol Metab. 1983 Aug; 57(2):254-61. . View in PubMed

Estrogen receptor and peroxidase activity in epithelial ovarian carcinomas J Natl Cancer Inst. 1981 Aug; 67(2):307-18. . View in PubMed

Cytomegalovirus inclusion diseaseIts occurrence in the myenteric plexus of a renal transplant patient. Arch Pathol Lab Med. 1980 Nov; 104(11):580-3. . View in PubMed

Animal model: Lead Encephalopathy in Neonatal Long-Evans Rats Poisoned via an Esophageal Catheter Am J Pathol. 1977 Feb; 86(2):485-8. . View in PubMed

Michael F. Press, M.D., Ph.D. is a professor in the Department of Pathology and co-leader of the Women’s Cancers Program. He received his M.D., Ph.D. and residency training at the University of Chicago. He was a member of the University of Chicago faculty for seven years before joining the faculty of the University of Southern California in 1988. Dr. Press is currently the director for the Breast Cancer International Research Group Central Laboratory, the coordinator of the Breast Cancer Program at USC Norris Cancer Center and holds the Harold E. Lee Chair in Cancer Research in the USC Norris Cancer Center. His research interests are molecular genetic alterations in breast and gynecologic cancers.
sc ctsi logoPowered by SC CTSI

Affiliated Faculty at UPC